Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02072928|
Recruitment Status : Completed
First Posted : February 27, 2014
Results First Posted : December 15, 2017
Last Update Posted : December 15, 2017
|Condition or disease||Intervention/treatment|
|Urinary Incontinence||Biological: botulinum toxin Type A|
|Study Type :||Observational|
|Actual Enrollment :||55 participants|
|Actual Study Start Date :||January 28, 2014|
|Actual Primary Completion Date :||September 30, 2015|
|Actual Study Completion Date :||September 30, 2015|
Patients with incontinence from NDO due to spinal injury or MS prescribed BOTOX® (Botulinum toxin Type A) as standard of care in clinical practice.
Biological: botulinum toxin Type A
botulinum toxin Type A (BOTOX®) prescribed as standard of care in clinical practice.
- Change From Baseline in Anticholinergic Drug Use [ Time Frame: Baseline, 9 Months ]Anticholinergic drug use was collected the 9 months before the baseline Botox® treatment and the 9 months following the baseline Botox® treatment. Total anticholinergic drug use in the 9 months following the baseline Botox® treatment is noted.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02072928
|Edegem, Belgium, 2650|
|CHU de Liège|
|Esneux, Belgium, 4130|
|Ghent, Belgium, 9000|
|Centre Hospitalier Regional de Huy|
|HUY, Belgium, 4500|
|Leuven, Belgium, 3000|
|Maria Ziekenhuis Noord-Limburg|
|Overpelt, Belgium, 3900|
|Study Director:||Medical Director||Allergan|